ANI Pharmaceuticals (NASDAQ:ANIP) Cut to Sell at StockNews.com

StockNews.com lowered shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a sell rating in a report issued on Monday morning.

ANIP has been the topic of a number of other research reports. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday. Finally, Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $79.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $59.68 on Monday. The company’s fifty day moving average price is $57.42 and its 200-day moving average price is $58.10. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -108.51 and a beta of 0.74. ANI Pharmaceuticals has a one year low of $52.50 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,300 shares of company stock valued at $584,009. Insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of ANIP. US Bancorp DE increased its position in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock valued at $33,000 after acquiring an additional 531 shares during the period. KBC Group NV boosted its stake in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock valued at $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $166,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at about $200,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.